Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. reports developments tied to its antimicrobial wound care business, including commercialization of the revyve product line in the United States and Canada. The company is developing and marketing wound care treatments that target biofilms and wound bacteria, with revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser holding U.S. FDA 510(k) clearance; the gel and gel spray are also approved by Health Canada.
Recurring news includes financial results, distribution and sales-agent agreements, regulatory and quality-system updates, and scientific publications or conference presentations involving chronic wound and burn care research. Company updates also discuss operating expenses, continuing operations, and the discontinued animal health contract manufacturing activities that have affected recent results.
Kane Biotech (OTC: KNBIF) announced a U.S. commercialization expansion on March 10, 2026, signing a distribution agreement with Marathon Medical and multiple independent U.S. contract sales representative agreements. Marathon provides federally authorized procurement pathways into the VA, DOD, and IHS, and Kane is building a contract sales team through 2026.
Kane Biotech (KNBIF) announced publication of a peer-reviewed article in the International Wound Journal on revyve Antimicrobial Wound Gel. The study reports a thermo-reversible gel with 99.99%–99.9999% bacterial reductions within 30 minutes, sustained in vitro activity up to 7 days, and porcine biocompatibility results. revyve holds US FDA 510(k) clearance and Health Canada approval, and the paper is first-authored by Kane R&D lead Dr. Jeyachchandran Visvalingam with collaborators from University of Miami.
Kane Biotech (OTC:KNBIF) signed non-exclusive U.S. distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ) on Feb. 19, 2026.
The products are FDA 510(k) cleared and Health Canada approved. Life Biologics will distribute nationally in advanced wound care; Patient Care Medical will cover Louisiana, Mississippi and the Gulf Coast. Preparations for initial shipments are underway in the near term.
Kane Biotech (OTC:KNBIF) received U.S. FDA 510(k) clearance for revyve® Antimicrobial Skin and Wound Cleanser, cleared for mechanical cleansing and debridement across a broad range of acute and chronic dermal lesions.
Manufacturing technology transfer and scale-up are planned later in 2026, and Kane expanded ISO 13485:2016/MDSAP certification to include distribution and wound cleansers, aligning with the FDA QMSR effective February 2026 to support multi‑jurisdiction regulatory filings.
Kane Biotech (OTC:KNBIF) has restarted commercial activities for its revyve Antimicrobial Wound Gel product line in the U.S. and Canada and appointed two North American business development VPs.
The product is US FDA 510(k) cleared and Health Canada approved; Kane signed non-exclusive U.S. distribution agreements and converted its Canadian distributor to a non-exclusive arrangement, with initial shipments expected in the near term.
Kane Biotech (OTC:KNBIF) closed a non-brokered private placement on Dec 18, 2025, issuing 14,000,000 common shares at $0.05 per share for gross proceeds of $700,000 to an insider.
Proceeds are earmarked for working capital and general corporate purposes. All securities carry a four-month-and-one-day hold period. The closing remains subject to final approval by the TSX Venture Exchange. The transaction is a related‑party deal under MI 61-101 and the company relied on exemptions from formal valuation and minority approval requirements.
Kane Biotech (OTC:KNBIF) presented new clinical and scientific data at the Innovations in Wound Healing Annual Meeting in Key West, Florida, held December 11–14, 2025.
Highlights include case study outcomes showing improved healing trajectories with Kane’s advanced wound gel across chronic wounds, demonstrated versatility across application frequencies, dressings and wound types, new findings in a chronic radiation-induced Achilles ulcer, and data in hidradenitis suppurativa (HS) suggesting reduced infection burden. The presentations also included market adoption insights. The company noted that revyve Antimicrobial Wound Gel and revyve Spray are FDA cleared and Health Canada approved.
Kane Biotech (OTC:KNBIF) announced that Health Canada approved revyve Antimicrobial Wound Gel Spray for use in Canada on December 10, 2025. The product was previously cleared under the FDA 510(k) process.
The approval gives Canadian clinicians and patients access to a new option for managing burns, large surface area wounds and ulcers, and the company said it will work with healthcare partners and distributors on access and education. Kane also noted a recent FDA submission for revyve Antimicrobial Wound and Skin Cleanser as a third product in the revyve line.
Kane Biotech (OTC:KNBIF) reported third quarter 2025 results showing a sharp revenue decline to $8,499 from $1,282,698 year‑earlier as prior animal‑health manufacturing and a US distribution agreement terminated.
Third quarter gross loss was $(5,128) versus prior gross profit of $558,754; net loss was $(607,345). Cash on hand was $939,062. Operating expenses fell to $538,306 from $1,170,064, mainly from staff and compensation reductions.
Corporate progress: U.S. revyve case series exceeded enrollment targets (28 of a 25 target), strong clinical readouts (97% mean wound area reduction in 4 weeks; 100% diabetic wound closure 12 weeks in presented cases), a six‑log microbial reduction in burn preclinical data, and completion of a clearance submission for revyve Antimicrobial Wound Cleanser.
Kane Biotech (OTC:KNBIF) announced a non‑brokered private placement to issue up to 16 million common shares at $0.05 per share for gross proceeds of up to $800,000. Proceeds are intended for working capital and general corporate purposes. Certain insiders may participate. Closing is expected on or about December 17, 2025. All issued shares will be subject to a four‑month and one‑day hold period. The Offering is subject to necessary approvals, including the TSX Venture Exchange. Securities will not be registered in the United States and may not be offered or sold in the U.S. or to U.S. persons.